Synonyms: LY-333531
Compound class:
Synthetic organic
Comment: The structure and activity of ruboxistaurin (as LY333531) is reported in [4]. Ruboxistaurin is selective for the PKC isozymes PKCβI and PKCβII compared to PKCα.
This compound is proposed to have therapeutic potential for treatment of nephropathy and vascular complications associated with diabetes mellitus [1]. Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
This is an experimental compound with potential to treat the peripheral retinopathy associated with diabetes mellitus. |
Mechanism Of Action and Pharmacodynamic Effects |
Inhibition of PKCβ reduces downstream induction of vascular endothelial growth factor (VEGF)-stimulated neo-angiogenesis and may therefore reduce the abnormal vascularisation which causes diabetic retinopathy. The compound may also protect the diabetic vasculature from inflammatory damage resulting from advanced glycation end product (AGE) production [6,8]. |